GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CohBar Inc (OTCPK:CWBR) » Definitions » Gross Profit

CohBar (CohBar) Gross Profit : $0.00 Mil (TTM As of Jun. 2023)


View and export this data going back to 2015. Start your Free Trial

What is CohBar Gross Profit?

CohBar's gross profit for the three months ended in Jun. 2023 was $0.00 Mil. CohBar's gross profit for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. CohBar's gross profit for the three months ended in Jun. 2023 was $0.00 Mil. CohBar's Revenue for the three months ended in Jun. 2023 was $0.00 Mil. Therefore, CohBar's Gross Margin % for the quarter that ended in Jun. 2023 was N/A%.

CohBar had a gross margin of N/A% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage


CohBar Gross Profit Historical Data

The historical data trend for CohBar's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CohBar Gross Profit Chart

CohBar Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CohBar Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CohBar's Gross Profit

For the Biotechnology subindustry, CohBar's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CohBar's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CohBar's Gross Profit distribution charts can be found below:

* The bar in red indicates where CohBar's Gross Profit falls into.



CohBar Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

CohBar's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as

Gross Profit (A: Dec. 2022 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

CohBar's Gross Profit for the quarter that ended in Jun. 2023 is calculated as

Gross Profit (Q: Jun. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

CohBar's Gross Margin % for the quarter that ended in Jun. 2023 is calculated as

Gross Margin % (Q: Jun. 2023 )=Gross Profit (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


CohBar  (OTCPK:CWBR) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

CohBar had a gross margin of N/A% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage


CohBar Gross Profit Related Terms

Thank you for viewing the detailed overview of CohBar's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


CohBar (CohBar) Business Description

Traded in Other Exchanges
N/A
Address
1455 Adams Drive, Suite 2050, Menlo Park, CA, USA, 94025
CohBar Inc is a biotechnology company. It is engaged in the research and development of mitochondria-based therapeutics (MBTs) to treat various diseases associated with aging and metabolic dysfunction. The product portfolio of the company includes drugs such as CB4209 and CB4211, SHLP-6, SHLP-2, and new MBTs, these address a broad range of age-related diseases, including obesity, fatty liver disease, Type-2 diabetes, cancer, cardiovascular and neurodegenerative diseases. Geographically all the operations of the group functioned through the region of the United States.
Executives
Stephanie Tozzo director C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Misha Petkevich director C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Joanne Yun director C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Joseph J. Sarret director, officer: Chief Executive Officer C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Carol Nast director C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Kenneth C Cundy officer: Chief Scientific Officer 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Jeffrey Francis Biunno officer: CFO, Treasurer and Secretary 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Steven B Engle officer: Chief Executive Officer C/O XOMA LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
David Greenwood director 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Phyllis Gardner director 618 MIRADA AVENUE, STANFORD CA 94305
Philippe Calais director C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
John Amatruda director 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Simon Allen officer: Chief Executive Officer C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Albion Fitzgerald director 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Jon Leland Stern director, officer: Chief Executive Officer 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025